Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | -11.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.27 | N/A | -11.57% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions and the impact on future performance. They are focused on navigating these challenges.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
The earnings report indicates that ACADIA Pharmaceuticals is facing challenges, as reflected in their EPS miss. The stock reacted negatively, dropping 0.9%, likely due to investor concerns about the company's current performance and lack of guidance. Without clear direction, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DT MIDSTREAM INC
Feb 25, 2022